CSPC PHARMA (01093): The chemical innovative drug SYH2083 eye drops has received clinical trial approval in China.

CSPC PHARMA (01093) announced that the innovative first-class chemical drug SYH2083 eye drops developed by the group has been approved by the National Medical Products Administration of the People's Republic of China and can conduct clinical trials in China. This product is a small-molecule ophthalmic formulation with a novel mechanism of action that can reduce pro-inflammatory signals by decreasing the adhesion and activation of T lymphocytes, thereby treating ocular surface inflammation-related diseases. Preclinical studies have shown that this product exhibits significant pharmacological activity in a mouse dry eye model, with a clear mechanism of action, indicating good potential for clinical development. The clinical trial approved for this indication is for dry eye disease, and the product also has the potential to expand to other inflammatory ocular surface diseases such as allergic conjunctivitis in the future. The approval of the clinical trial for this product will further enrich the group's pipeline of innovative drugs in the field of ophthalmology.